Mar
12
2020 |
US FDA Grants Fast Track Designation to Jardiance® for the Treatment of Chronic Kidney Disease
FDA Fast Track designation is for the investigation of potential new therapies that treat serious conditions and fulfill an unmet medical need.
May
2
2019 |
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for which no targeted medical therapies exist.